- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07832006
Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
A Prospective Study of Irreversible Electroporation Combined With Lenvatinib and Sintilimab for Conversion Therapy in Patients With Advanced Hepatocellular Carcinoma
Advanced hepatocellular carcinoma (HCC) remains a major therapeutic challenge. Although targeted therapy combined with immune checkpoint inhibitors has improved clinical outcomes, the objective response rate and conversion surgery rate remain suboptimal. Irreversible electroporation (IRE) is a non-thermal ablation technique that can induce tumor cell death while preserving surrounding vascular and biliary structures. Emerging evidence suggests that IRE may enhance anti-tumor immunity and synergize with systemic therapy.
This prospective, single-center, open-label study aims to evaluate the efficacy and safety of IRE combined with lenvatinib and sintilimab in patients with advanced HCC. Eligible patients with unresectable CNLC stage IIa, IIb, or IIIa disease will receive standard targeted therapy and immunotherapy with or without IRE according to treatment allocation. The primary endpoints are objective response rate (ORR) and conversion surgery rate. Secondary endpoints include time to response (TTR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs).
The study is expected to provide evidence regarding the role of IRE in enhancing tumor response and increasing the likelihood of curative-intent surgical resection in patients with advanced HCC.
연구 개요
상세 설명
-
Background
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. For patients with advanced-stage disease, systemic therapy based on tyrosine kinase inhibitors and immune checkpoint inhibitors has become the standard of care. However, only a proportion of patients achieve meaningful tumor regression, and the rate of successful conversion to surgical resection remains limited.
Irreversible electroporation (IRE) is a novel non-thermal local ablative technique that induces apoptosis through permanent disruption of cellular membranes. Unlike thermal ablation modalities, IRE preserves major blood vessels and bile ducts, making it particularly suitable for tumors adjacent to critical structures. Furthermore, preclinical and clinical studies have suggested that IRE may induce immunogenic cell death and augment anti-tumor immune responses.
-
Study Objectives
The primary objective of this study is to evaluate whether the addition of IRE to targeted therapy and immunotherapy improves tumor response and conversion surgery rate in patients with advanced HCC.
The secondary objective is to assess survival outcomes and treatment-related safety.
-
Study Design
This is a prospective, single-center, open-label interventional study. Patients with advanced HCC meeting the eligibility criteria will receive either:
IRE combined with lenvatinib and sintilimab; or Lenvatinib and sintilimab alone.
Tumor response will be evaluated according to RECIST version 1.1 and mRECIST criteria. Patients will undergo regular imaging assessments and multidisciplinary evaluation to determine eligibility for curative-intent surgical resection.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Jiayue Li
- 전화번호: 010-69156874
- 이메일: pumchkyc@126.com
연구 장소
-
-
No. 1 Shuaifuyuan, Dongcheng District, Beijing, China
-
Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China, 중국, 100730
- 모병
- Peking Union Medical College Hospital
-
연락하다:
- Longfang Miao
- 전화번호: 010-69155709
- 이메일: pumchjyc@126.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age 18 to 75 years.
- Clinically or pathologically confirmed hepatocellular carcinoma (HCC).
- Unresectable HCC corresponding to CNLC stage IIa, IIb, or IIIa, without extrahepatic metastasis.
- At least one measurable lesion according to RECIST version 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Child-Pugh class A or B liver function.
- Adequate organ function, including an absolute neutrophil count ≥1.5 × 10⁹/L; platelet count ≥75 × 10⁹/L; hemoglobin ≥80 g/L; serum creatinine ≤1.5 × the upper limit of normal (ULN) or creatinine clearance ≥50 mL/min; total bilirubin ≤3 × ULN; and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN.
- Suitable for treatment with lenvatinib and sintilimab according to institutional standards.
- Able to understand and sign written informed consent.
Exclusion Criteria:
- Presence of extrahepatic metastasis.
- Previous treatment with irreversible electroporation.
- Prior systemic therapy that precludes treatment with lenvatinib or sintilimab.
- Diffuse infiltrative HCC not suitable for IRE evaluation.
- Uncontrolled ascites, hepatic encephalopathy, or active gastrointestinal bleeding.
- Active severe infection requiring systemic treatment.
- Active tuberculosis.
- Uncontrolled hepatitis B virus replication despite antiviral therapy.
- Clinically significant cardiovascular disease, including uncontrolled hypertension, recent myocardial infarction, unstable angina, or severe arrhythmia.
- Concurrent malignancy requiring active treatment.
- Pregnancy or breastfeeding.
- Any condition that, in the investigator's judgment, would interfere with study participation or interpretation of the study results.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: IRE + Lenvatinib + Sintilimab
Patients receive irreversible electroporation combined with lenvatinib and sintilimab as conversion therapy. |
Percutaneous or intraoperative irreversible electroporation performed according to institutional standards. Oral administration according to body weight and prescribing information. 200 mg intravenously every 3 weeks. |
|
활성 비교기: Lenvatinib + Sintilimab
Patients receive standard targeted therapy and immunotherapy without IRE. |
Oral administration according to body weight and prescribing information. 200 mg intravenously every 3 weeks. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective Response Rate (ORR)
기간: From treatment initiation until conversion surgery, first documented disease progression, or treatment discontinuation, whichever occurs first, with tumor response assessed approximately every month, up to 24 months.
|
The proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST version 1.1. |
From treatment initiation until conversion surgery, first documented disease progression, or treatment discontinuation, whichever occurs first, with tumor response assessed approximately every month, up to 24 months.
|
|
Conversion Surgery Rate
기간: From treatment initiation until curative-intent conversion surgery, disease progression, or treatment discontinuation, whichever occurs first, assessed up to 24 months.
|
Proportion of patients who undergo curative-intent surgical resection after study treatment based on multidisciplinary evaluation. |
From treatment initiation until curative-intent conversion surgery, disease progression, or treatment discontinuation, whichever occurs first, assessed up to 24 months.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-Free Survival (PFS)
기간: Up to 24 months
|
Time from treatment initiation to disease progression or death. |
Up to 24 months
|
|
Overall Survival (OS)
기간: Up to 24 months
|
Time from treatment initiation to death from any cause. |
Up to 24 months
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- I-24PJ2181
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .